Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:7:501-5.
doi: 10.2147/NDT.S24153. Epub 2011 Aug 26.

An in vitro evaluation of guanfacine as a substrate for P-glycoprotein

Affiliations

An in vitro evaluation of guanfacine as a substrate for P-glycoprotein

Nancy K Gillis et al. Neuropsychiatr Dis Treat. 2011.

Abstract

Background: With a US Food and Drug Administration-labeled indication to treat attention-deficit/hyperactivity disorder (ADHD), the nonstimulant guanfacine has become the preferred α(2)-agonist for ADHD treatment. However, significant interindividual variability has been observed in response to guanfacine. Consequently, hypotheses of a contributing interaction with the ubiquitously expressed drug transporter, P-glycoprotein (P-gp), have arisen. We performed an in vitro study to determine if guanfacine is indeed a substrate of P-gp.

Methods: Intracellular accumulation of guanfacine was compared between P-gp expressing LLC-PK1/MDR1 cells and P-gp-negative LLC-PK1 cells to evaluate the potential interaction between P-gp and guanfacine. Cellular retention of guanfacine was analyzed using a high-performance liquid chromatographic-ultraviolet method. Rhodamine6G, a known P-gp substrate, was included in the study as a positive control.

Results: At guanfacine concentrations of 50 μM and 5 μM, intracellular accumulation of guanfacine in LLC-PK1/MDR1 cells was, 35.9% ± 4.8% and 49.0% ± 28.3% respectively, of that in LLC-PK1 cells. In comparison, the concentration of rhodamine6G, the positive P-gp substrate, in LLC-PK1/MDR1 cells was only 5% of that in LLC-PK1 cells.

Conclusion: The results of the intracellular accumulation study suggest that guanfacine is, at best, a weak P-gp substrate. Therefore, it is unlikely that P-gp, or any genetic variants thereof, are a determining factor in the interindividual variability of response observed with guanfacine therapy.

Keywords: P-glycoprotein; guanfacine; intracellular uptake; substrate.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Intracellular concentrations of guanfacine in LLC-PK1 and LLC-PK1/MDR1 cells. Each column represents the mean percentages of intracellular guanfacine concentrations relative to that in LLC-PK1 cells, with a bar representing the standard deviation of three independent measurements. Notes: *P < 0.05; **P < 0.01.

Similar articles

Cited by

References

    1. Sorkin EM, Heel RC. Guanfacine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs. 1986;31(4):301–336. - PubMed
    1. Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: Evidence for alpha-2 receptor subtypes. J Neurosci. 1988;8(11):4287–4298. - PMC - PubMed
    1. Avery R, Franowicz JCS, Studholme C, van Dyck CH, Arnsten AFT. The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex and improves accuracy in monkeys performing a spatial working memory task. Neuropsychopharmacology. 2000;23(3):240–249. - PubMed
    1. Crenshaw TM, Kavale KA, Forness SR, Reeve RE. Attention deficit hyperactivity disorder and the efficacy of stimulant medication: A meta-analysis. In: Scruggs TE, Mastropieri MA, editors. Advances in Learning and Behavioral Disabilities. Greenwich, CT: JAI Press; 1999.
    1. Biederman J, Melmed RD, Patel A, et al. for SPD503 Study Group. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73–e84. - PubMed